NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$64.54 -1.67 (-2.52 %)
(As of 12/17/2018 08:23 AM ET)
Previous Close$66.21
Today's Range$64.10 - $67.29
52-Week Range$28.85 - $74.73
Volume363,697 shs
Average Volume490,801 shs
Market Capitalization$2.15 billion
P/E Ratio66.54
Dividend YieldN/A
Beta1.57
BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
Previous Symbol
CUSIPN/A
Phone610-729-7000

Debt

Debt-to-Equity Ratio0.66
Current Ratio2.68
Quick Ratio2.50

Price-To-Earnings

Trailing P/E Ratio66.54
Forward P/E Ratio35.66
P/E Growth3.58

Sales & Book Value

Annual Sales$286.78 million
Price / Sales7.49
Cash Flow$1.8713 per share
Price / Cash Flow34.49
Book Value$7.70 per share
Price / Book8.38

Profitability

EPS (Most Recent Fiscal Year)$0.97
Net Income$-15,950,000.00
Net Margins4.34%
Return on Equity22.56%
Return on Assets11.15%

Miscellaneous

Employees1,600
Outstanding Shares33,300,000
Market Cap$2.15 billion
OptionableOptionable

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) issued its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.21. The medical research company had revenue of $100 million for the quarter, compared to analysts' expectations of $97.89 million. BioTelemetry had a return on equity of 22.56% and a net margin of 4.34%. The company's revenue for the quarter was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 EPS. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

5 brokerages have issued 12 month target prices for BioTelemetry's shares. Their forecasts range from $41.00 to $90.00. On average, they expect BioTelemetry's share price to reach $63.20 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Press coverage about BEAT stock has been trending somewhat positive on Monday, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioTelemetry earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of BioTelemetry's key competitors?

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 54)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 43)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 48)
  • Mr. Tim Raher, Sr. VP of HR

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.89%), Vanguard Group Inc. (5.71%), Vanguard Group Inc (5.71%), Dimensional Fund Advisors LP (4.13%), Macquarie Group Ltd. (3.76%) and Credit Suisse AG (2.48%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Bank of New York Mellon Corp, Pembroke Management LTD, Thompson Siegel & Walmsley LLC, Russell Investments Group Ltd., Allianz Asset Management GmbH, Strs Ohio and Falcon Point Capital LLC. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Which major investors are buying BioTelemetry stock?

BEAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Loomis Sayles & Co. L P, Fuller & Thaler Asset Management Inc., Credit Suisse AG, Point72 Asset Management L.P., First Trust Advisors LP, Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $64.54.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $2.15 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by MarketBeat.com Staff

Featured Article: Hedge Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel